Podcasts about Flibanserin

Drs Madhukar Trivedi and Anita Clayton discuss how to approach patients with sexual dysfunction who are being treated for major depressive disorder. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984459). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Depression https://emedicine.medscape.com/article/286759-overview Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/19440080/ Citizen Petition: Sexual Side Effects of SSRIs and SNRIs https://pubmed.ncbi.nlm.nih.gov/29733031/ Association of Major Depression With Sexual Dysfunction in Men https://pubmed.ncbi.nlm.nih.gov/23645187/ The Changes in Sexual Functioning Questionnaire (CSFQ): Development, Reliability, and Validity https://pubmed.ncbi.nlm.nih.gov/9493486/ Structured Review of the Use of the Arizona Sexual Experiences Scale in Clinical Settings https://pubmed.ncbi.nlm.nih.gov/32236977/ Hypoactive Sexual Desire Disorder: A Review of Epidemiology, Biopsychology, Diagnosis, and Treatment https://pubmed.ncbi.nlm.nih.gov/27872021/ Erectile Dysfunction https://pubmed.ncbi.nlm.nih.gov/31030826/ Sexual Dysfunction With Major Depressive Disorder and Antidepressant Treatments: Impact, Assessment, and Management https://pubmed.ncbi.nlm.nih.gov/35255754/ Overview of the Rapid Antidepressant Effects Observed in the Zuranolone Clinical Development Program https://journals.lww.com/greenjournal/Abstract/2022/05001/Overview_of_the_Rapid_Antidepressant_Effects.161.aspx Flibanserin prescribing information https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf

To celebrate Valentine's Day on February 14th, Do You Really Know is ready to cover a whole host of subjects linked to love and desire! From trends like sologamy and sneating, to the emergence of female viagra, spend all week learning about the concepts that surround our love lives in the 21st century. What is female viagra? It's been over two decades now since viagra was first approved for use in 1998, the little blue pill from Pfizer becoming the first oral treatment for erectile dysfunction. Its use has steadily increased over the years, with the NHS reporting just under 3 million prescriptions in 2016, compared to 1 million in 2006. Its success has led pharmaceutical companies to look for a female equivalent. In 2015, the American Food & Drug Authority approved a pink pill called Flibanserin, marketed as Addyi, which became known as female viagra. How does it work? Let's cut to the chase then; does female viagra really work? What can be done to help women who want to boost their libido? In under 3 minutes, we answer your questions! To listen to the last episodes, you can click here: What is demisexuality? What is sologamy? What is intersectionality? A podcast written and realised by Joseph Chance. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the December issue of DTB. They discuss a recently published national report on overprescribing of medicines. The editors talk about a study that assessed the accuracy of home blood pressure monitors (https://dtb.bmj.com/content/59/12/179) and highlight a safety alert on topical steroid withdrawal reactions (https://dtb.bmj.com/content/59/12/184). They also review an article on the US Food and Drug Administration's decision to license bremelanotide and flibanserin for 'hypoactive sexual desire disorder' in women (https://dtb.bmj.com/content/59/12/185).

Elliot en Eva praten over hoe het hebben van veel én weinig seks kan leiden tot diagnoses van mentale stoornissen. Waar Elliot over praat: Nymfomanie, Satyriasis, Parafilie en Hyperseksualiteit. Waar Eva over praat: Asexuality was Considered a Disorder?!, How the DSM (sort of) came to recognise “asexuality” as (sort of) legit, a(n his)story in progress of the FDA, flibanserin, pathologising discourse… and ace community, Asexuality in the DSM-5, Standpunt NVVS ten aanzien van Flibanserin en Flibanserin Queer history: Female histeria Volg ons op instagram! @pridepraatpod Wil je iets kwijt? Iets tegen ons zeggen? Een essay voor ons schrijven? Stuur een mailtje! pridepraatpod@gmail.com

Chances are you’ve probably heard of the “ little blue pill” that gives men erections almost like magic. But have you ever heard of Flibanserin? This “female Viagra” is the topic of this week’s episode, where we start with a little science and biology but of course get into some history, learning about Erectile Dysfunction, Female Sexual Dysfunction and how their histories differ so vastly. Ranging from Mesopotamian spells that men used to cast on each other to ward off virility-stealers to the DSM-V and how its use and misuse affects women’s mental and sexual health to this day. In our Feminist Corner, we discuss the concept of “normal”, especially in the context of sexual dysfunction, and what the “Charmed Circle” is as well as how it’s used to understand sex in larger circles of society. Flibanserin deserves more of a role in the spotlight, so that’s exactly what we’re giving her!

Et oui, c’est la fin de l’année et qui dit fin de l’année dit Gala des grands crus et des piquettes du Pharmascope! Ne ratez donc pas ce 43ème épisode dans lequel Nicolas, Sébastien et Isabelle dévoilent les grands gagnants de célèbres catégories comme Les affaires simples et pas chères mais combien intéressantes ou encore L’étude musicale de l’année ! Les objectifs pour cet épisode sont: Comprendre le rôle de la cigarette électronique en cessation tabagiqueExpliquer les risques et les bénéfices associés à la flibansérineConnaître l’impact de la thérapie par ventilateur en dyspnée en soins palliatifsConnaître l’impact du port d’un masque et de bouchons pour les oreilles sur le sommeil chez les patients hospitalisésIdentifier des mesures pour diminuer la douleur et la peur associées aux injections intrasmusculaires en pédiatrie Ressources pertinentes en lien avec l’épisode Essai randomisé contrôlé comparant la cigarette électronique à la thérapie de remplacement de nicotine en cessation tabagiqueHajek P, Phillips-Waller A, Przulj D, et coll. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. N Engl J Med. 2019 Feb 14;380(7):629-637. Article portant sur l’approbation de la flibansérineWoloshin S, Schwartz LM. US Food and Drug Administration Approval of Flibanserin: Even the Score Does Not Add Up. JAMA Intern Med. 2016 Apr;176(4):439-42. Revue systématique évaluant l’efficacité et l’innocuité de la flibansérineJaspers L, Feys F, Bramer WM, et coll. Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis. JAMA Intern Med. 2016 Apr;176(4):453-62. Revue systématique évaluant l’efficacité du vinaigre en diabèteCheng LJ, Jiang Y, Wu XV, et coll. A systematic review and meta-analysis: Vinegar consumption on glycaemic control in adults with type 2 diabetes mellitus. J Adv Nurs. 2019 Oct 31. Étude observationnelle évaluant l’association entre la capacité à faire des push-up et le risque cardiovasculaireYang J, Christophi CA, Farioli A, et coll. Association Between Push-up Exercise Capacity and Future Cardiovascular Events Among Active Adult Men. JAMA Netw Open. 2019 Feb 1;2(2):e188341. Étude randomisée contrôlée évaluant l’efficacité d’un ventilateur pour la soulager la dyspnée en soins palliatifsKako J, Morita T, Yamaguchi T, et coll. Fan Therapy Is Effective in Relieving Dyspnea in Patients With Terminally Ill Cancer: A Parallel-Arm, Randomized Controlled Trial. J Pain Symptom Manage. 2018 Oct;56(4):493-500. Étude randomisée contrôlée évaluant l’efficacité du port d’un masque et de bouchons sur le sommeil durant une hospitalisationSweity S, Finlay A, Lees C, et coll. SleepSure: a pilot randomized-controlled trial to assess the effects of eye masks and earplugs on the quality of sleep for patients in hospital. Clin Rehabil. 2019 Feb;33(2):253-261. Étude randomisée contrôlée évaluant l’efficacité de la gomme à mâcher après une césarienneYenigul NN, Aydogan Mathyk B, Aslan Cetin B, et coll. Efficacy of chewing gum for improving bowel function after cesarean sections: a randomized controlled trial. J Matern Fetal Neonatal Med. 2019 Jan 4:1-6. Revue systématique évaluant l’efficacité de la gomme à mâcher après une césarienneCiardulli A, Saccone G, Di Mascio D, et coll. Chewing gum improves postoperative recovery of gastrointestinal function after cesarean delivery: a systematic review and meta-analysis of randomized trials. J Matern Fetal Neonatal Med. 2018 Jul;31(14):1924-1932. Étude randomisée contrôlée évaluant l’efficacité de la musicothérapie en pruritDemirtas S, Houssais C, Tanniou J, et coll. Effectiveness of a music intervention on pruritus: an open randomized prospective study. J Eur Acad Dermatol Venereol. 2019 Dec 15. Étude randomisée contrôlée évaluant l’efficacité d’un supplément de vitamine D aux soins intensifsGinde AA, Brower GD, Caterino JM, et coll.

Host: Michael Krychman, MD Flibanserin was one of the first FDA-approved medications for treatment of Hypoactive Sexual Desire Disorder in pre-menopausal women. But the drug's effectiveness has frequently been called into question, and the known side effects such as fainting, dizziness, and low blood pressure, many of which were found to be exacerbated by alcohol and hormonal contraception, created concerns for clinicians and patients alike. Host Dr. Michael Krychman talks with guest Dr. Lisa Larkin, women’s health internist and Director of the Women's Health Center at the University of Cincinnati College of Medicine, about the “Pink Viagra" pill, concerns around its safety and effectiveness, and the diagnosis and treatment of HDSS.

Interview with Ellen T. M. Laan, PhD, author of Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-Analysis, and Steven Woloshin, MD, MS, author of US Food and Drug Administration Approval of Flibanserin: Even the Score Does Not Add Up

Flibanserin was touted to be the female Viagra. Martha Henriques explains why it failed to live up to the hype.

Come imparare in breve tempo a "funzionare" in un Paese diverso, dove lingua, cultura e abitudini sono del tutto nuove e sconosciute? Quali difficoltà e opportunità dovranno affrontare tutti i componenti della famiglia? Il Trasferimento all'estero è il tema della prossima puntata di Nessuna è Perfetta. Maria Latella ne parla con i due esperti della settimana, Francesca Prandstraller, docente di risorse umane Francesca Prandstraller Docente di Risorse Umane e Organizzazione all'Università Bocconi ed autrice di "Vivere all'estero, guida per una relocation di successo" e Alberto Frausin, Ceo Carlsberg Italia. Si parlerà anche di Viagra Rosa dopo l'approvazione da parte della Food and Drug Administration americana del Flibanserin, un farmaco che secondo l'Agente provocatore della settimana, Vittorio Sgarbi, sarà un fallimento. Dello stesso parere la Sunday Girl Teresa Mannino che a quanto pare non ne ha proprio bisogno. Nel finale i consigli pratici della Coach Maria Serena Ciambellotti.

The first FDA approved female , Flibanserin(aka Adyii), will be available for consumers this October, 2015!  BUT, before you jump on the band wagon there's a few things about the creation of this drug you might want to hear about...  T&A talk with Liz Canner, director of the documentary film 'Orgasm inc.' about the race for the pharmaceutical's holy grail, how the 'need' for this drug even came into being, and big pharma's influence on our sexuality.  Fascinating, informative and uncomfortably eye-opening. Watch Orgasm inc. on Netflix, iTunes and everywhere else: www.orgasminc.org And, check out A's blog, 'Female : A Cautionary Tale'  for a deeper look at Flibanserin's story Show Notes In clinical trials, the subjects kept a daily diary and across the board, they recorded no significant daily increase in sexual desire (03:47) Who started the rumors of sexism and injustice at the FDA?  (05:09) Flibanserin was originally developed as an SSRI to treat depression, but it didn’t work as an anti-depressant  (05:40) What is ‘Conditioned Branding’?  (08:05) What is HSDD and is it real? (08:50) Drug companies have to have a clearly defined disease to start testing.  (09:45) The doctors that came together to define Female Sexual Dysfunction had ties to 22 drug companies. (10:28) Relevant Links & FULL Show Notes HERE: http://www.tatalksex.com/need-female--think-twice-before-you-pop-that-magic-pill/

Host: Michael Krychman, MD Guest: Sheryl A. Kingsberg, PhD Flibanserin's approval by the FDA for women with hypoactive sexual desire disorder (HSDD), touted by the press as the "Pink Viagra," created an enormous amount of media hype across the nation. But the facts on this drug's mechanism of action, intended benefits, adverse effects, and efficacy borne in clinical trials have gone largely under the radar. Joining Dr. Michael Krychman to discuss the rise of flibanserin and its key takeaways for clinicians is Dr. Sheryl Kingsberg, Chief of the Division of Behavioral Medicine in the Department of OB/GYN and Professor in the Departments of Reproductive Biology and Psychiatry at Case Medical Center University Hospitals in Cleveland, Ohio.

Host: Michael Krychman, MD Guest: Sheryl A. Kingsberg, PhD Flibanserin's approval by the FDA for women with hypoactive sexual desire disorder (HSDD), touted by the press as the "Pink Viagra," created an enormous amount of media hype across the nation. But the facts on this drug's mechanism of action, intended benefits, adverse effects, and efficacy borne in clinical trials have gone largely under the radar. Joining Dr. Michael Krychman to discuss the rise of flibanserin and its key takeaways for clinicians is Dr. Sheryl Kingsberg, Chief of the Division of Behavioral Medicine in the Department of OB/GYN and Professor in the Departments of Reproductive Biology and Psychiatry at Case Medical Center University Hospitals in Cleveland, Ohio.

Pegging, porn, and prostitution. A listener wrote in with a terrific message and mentioned pegging. Which sent us off on a bender about butt sex. Then, Dawn and Dylan talk about the new pink Viagra pill and why that name is so misleading. Flibanserin/Addyi is not what they're claiming it is, and there are better ways for most people to stimulate low desire. Dawn ran across a fun article about Pornhub viewers that found women (yes, it's heteronormative) watch more hardcore porn than men. We discuss. Finally, after nearly a month, we talk about the amazing Woodhull Sexual Freedom Summit. With amazing talks by Charlie Glickman, Joan Price, Monica Raye Simpson, and more, it was a powerful weekend of sex and human rights.   You know we love hearing from you, so here's how to reach us Call or text: 747-444-1840 (standard messaging rates apply) Email: info@sexgetsreal.com Contact form: Click here

I’m stunned by the extremes to which a pharmaceutical company will go when attempting to get FDA approval for some new drug. Take a look at the latest offering from privately-held Sprout Pharmaceuticals, who claim they now have a “female Viagra.” Yes, really. It is called Addyi. This drug is potentially dangerous, with some frightening side effects. They include an increased risk of syncope—temporary loss of consciousness—as well as severe low blood sugar, insomnia, dry mouth, fatigue, dizziness, sedation, and anxiety. Manufacturers warn if you decide to use it, not to drink alcohol. I wouldn’t touch Addyi with a ten foot pole. a failed antidepressant Addyi is actually Flibanserin—a failed antidepressant. Unlike Viagra, which is designed to bring more blood flow to male genitals if a man chooses to use it temporarily, Addyi is supposed to be used every day—long-term by women. It claims to enhance a woman’s sexual impulses by targeting, not your genitals but your brain. Flibanserin is similar to other selective serotonin reuptake inhibitors (SSRIs) like Prozac. Ironically these drugs are notorious not for increasing libido, but for blunting it. Some time ago, Big Pharma invented a whole new “illness” known as Hypoactive Sexual Desire Disorder, defined as “persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity.” Addyi is supposed to treat this. a mediocre aphrodisiac with scary side-effectsOriginally developed by family-owned Boehringer Ingelheim in Germany Flibanserin, after lengthy trails was judged to be ineffective as an antidepressant. Boehringer had submitted this drug to the FDA for approval in 2011. It was refused. Out of 1300 women who took part in trials, 15% dropped out due to unpleasant side effects. The FDA rejected the appeal, saying that whatever the drugs drug’s minor benefits might be they could not justify its nasty side effects. So Boehringer sold their invention to Sprout Pharmaceuticals in 2011. Who tried their luck with the FDA in 2013 and also got nowhere. However, Sprout’s persistence, massive lobbying and and financial investments amassed more than 60,000 supporting signatures so finally won FDA’s approval for the drug in August of 2015. This FDA approval stands next to many other applications which have won FDA approval in the past, showing that, when companies spend enough money, they can, in effect, force the FDA to approve many useless or dangerous drugs. Adriane Fugh-Berman MD, Pharmacology Professor at Georgetown University, describes Addyi as "a mediocre aphrodisiac with scary side-effects.” She adds, “The only thing that’s different is a clever, aggressive public relations campaign that Sprout Pharmaceuticals waged successfully.” FDA - a medical Gestapo Meanwhile, the outspoken Dr Mark Sircus makes his own assessment of the situation, which is well worth listening to. Sircus says, “Most doctors and medical associations just do not get that women are different from men sexually. They do not have genitals that function independent of their hearts and minds. The feminine principle is pretty much dead in modern civilization and especially at the FDA, which runs like the SS, a medical Gestapo. The FDA again proves what type of organization it is exposing women in America to the dangers and horrors of pharmaceutical drugs. They are the most unnatural organization in the world poisoning people instead of helping.” Need I say more? If you want to learn about safe natural aphrodisiacs that not only work but are a delight to use, I’ll be covering some of my favorites on our next two videocasts. Look forward to seeing you then.

I’m stunned by the extremes to which a pharmaceutical company will go when attempting to get FDA approval for some new drug. Take a look at the latest offering from privately-held Sprout Pharmaceuticals, who claim they now have a “female Viagra.” Yes, really. It is called Addyi. This drug is potentially dangerous, with some frightening side effects. They include an increased risk of syncope—temporary loss of consciousness—as well as severe low blood sugar, insomnia, dry mouth, fatigue, dizziness, sedation, and anxiety. Manufacturers warn if you decide to use it, not to drink alcohol. I wouldn’t touch Addyi with a ten foot pole. a failed antidepressant Addyi is actually Flibanserin—a failed antidepressant. Unlike Viagra, which is designed to bring more blood flow to male genitals if a man chooses to use it temporarily, Addyi is supposed to be used every day—long-term by women. It claims to enhance a woman’s sexual impulses by targeting, not your genitals but your brain. Flibanserin is similar to other selective serotonin reuptake inhibitors (SSRIs) like Prozac. Ironically these drugs are notorious not for increasing libido, but for blunting it. Some time ago, Big Pharma invented a whole new “illness” known as Hypoactive Sexual Desire Disorder, defined as “persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity.” Addyi is supposed to treat this. a mediocre aphrodisiac with scary side-effectsOriginally developed by family-owned Boehringer Ingelheim in Germany Flibanserin, after lengthy trails was judged to be ineffective as an antidepressant. Boehringer had submitted this drug to the FDA for approval in 2011. It was refused. Out of 1300 women who took part in trials, 15% dropped out due to unpleasant side effects. The FDA rejected the appeal, saying that whatever the drugs drug’s minor benefits might be they could not justify its nasty side effects. So Boehringer sold their invention to Sprout Pharmaceuticals in 2011. Who tried their luck with the FDA in 2013 and also got nowhere. However, Sprout’s persistence, massive lobbying and and financial investments amassed more than 60,000 supporting signatures so finally won FDA’s approval for the drug in August of 2015. This FDA approval stands next to many other applications which have won FDA approval in the past, showing that, when companies spend enough money, they can, in effect, force the FDA to approve many useless or dangerous drugs. Adriane Fugh-Berman MD, Pharmacology Professor at Georgetown University, describes Addyi as "a mediocre aphrodisiac with scary side-effects.” She adds, “The only thing that’s different is a clever, aggressive public relations campaign that Sprout Pharmaceuticals waged successfully.” FDA - a medical Gestapo Meanwhile, the outspoken Dr Mark Sircus makes his own assessment of the situation, which is well worth listening to. Sircus says, “Most doctors and medical associations just do not get that women are different from men sexually. They do not have genitals that function independent of their hearts and minds. The feminine principle is pretty much dead in modern civilization and especially at the FDA, which runs like the SS, a medical Gestapo. The FDA again proves what type of organization it is exposing women in America to the dangers and horrors of pharmaceutical drugs. They are the most unnatural organization in the world poisoning people instead of helping.” Need I say more? If you want to learn about safe natural aphrodisiacs that not only work but are a delight to use, I’ll be covering some of my favorites on our next two videocasts. Look forward to seeing you then.

I'm stunned by the extremes to which a pharmaceutical company will go when attempting to get FDA approval for some new drug. Take a look at the latest offering from privately-held Sprout Pharmaceuticals, who claim they now have a “female Viagra.” Yes, really. It is called Addyi. This drug is potentially dangerous, with some frightening side effects. They include an increased risk of syncope—temporary loss of consciousness—as well as severe low blood sugar, insomnia, dry mouth, fatigue, dizziness, sedation, and anxiety. Manufacturers warn if you decide to use it, not to drink alcohol. I wouldn't touch Addyi with a ten foot pole. Addyi is actually Flibanserin—a failed antidepressant. Unlike Viagra, which is designed to bring more blood flow to male genitals if a man chooses to use it temporarily, Addyi is supposed to be used every day—long-term by women. It claims to enhance a woman's sexual impulses by targeting, not your genitals but your brain. Flibanserin is similar to other selective serotonin reuptake inhibitors (SSRIs) like Prozac. Ironically these drugs are notorious not for increasing libido, but for blunting it. Some time ago, Big Pharma invented a whole new “illness” known as Hypoactive Sexual Desire Disorder, defined as “persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity.” Addyi is supposed to treat this. Originally developed by family-owned Boehringer Ingelheim in Germany Flibanserin, after lengthy trails was judged to be ineffective as an antidepressant. Boehringer had submitted this drug to the FDA for approval in 2011. It was refused. Out of 1300 women who took part in trials, 15% dropped out due to unpleasant side effects. The FDA rejected the appeal, saying that whatever the drugs drug's minor benefits might be they could not justify its nasty side effects. So Boehringer sold their invention to Sprout Pharmaceuticals in 2011. Who tried their luck with the FDA in 2013 and also got nowhere. However, Sprout's persistence, massive lobbying and and financial investments amassed more than 60,000 supporting signatures so finally won FDA's approval for the drug in August of 2015. This FDA approval stands next to many other applications which have won FDA approval in the past, showing that, when companies spend enough money, they can, in effect, force the FDA to approve many useless or dangerous drugs. Adriane Fugh-Berman MD, Pharmacology Professor at Georgetown University, describes Addyi as "a mediocre aphrodisiac with scary side-effects.” She adds, “The only thing that's different is a clever, aggressive public relations campaign that Sprout Pharmaceuticals waged successfully.” Meanwhile, the outspoken Dr Mark Sircus makes his own assessment of the situation, which is well worth listening to. Sircus says, “Most doctors and medical associations just do not get that women are different from men sexually. They do not have genitals that function independent of their hearts and minds. The feminine principle is pretty much dead in modern civilization and especially at the FDA, which runs like the SS, a medical Gestapo. The FDA again proves what type of organization it is exposing women in America to the dangers and horrors of pharmaceutical drugs. They are the most unnatural organization in the world poisoning people instead of helping.” Need I say more? If you want to learn about safe natural aphrodisiacs that not only work but are a delight to use, I'll be covering some of my favorites on our next two videocasts. Look forward to seeing you then.

Looks like we made it!  We celebrate our 100th episode with a live audience and a panel of all-star guests in San Francisco's Hemlock Tavern.  It was a festive night, indeed.  Guests include: comedian Reggie Steele; filmmaker Angela Tabora; blogger and TV show producer Gabi Moskowitz "The BrokeAss Gourmet"'; and Pop Culture Wiz Kid  Dino-Ray Ramos.  And in the most serendipitous of John Stamos Minutes, our show took place on JS's birthday and we had a cake with his face on it.

This week's episode features two very different topics. Patrick Chovanec of Silvercrest Asset Management joins Cardiff Garcia and Matt Klein to discuss devaluation of the renminbi and other imbalances in the Chinese economy. FT correspondents Shannon Bond and David Crow examine concerns raised over Flibanserin, the newly approved drug for hypoactive sexual desire disorder. See acast.com/privacy for privacy and opt-out information.

What happens when you see a stranger in a bar and realize you recognize them from a match on an online dating site? Also, the FDA has approved the female Viagra pill, but it is more like an antidepressant than an aphrodisiac.  Finally, are thong underwear trending down?  The Millennials of America say yes.

The 'Sterds™ offer their expert* advice and well-researched* opinions on the upcoming mass production and eventual release of a drug called flibanserin (a.k.a. the "female viagra"). Creative Commons Music: "Habitual Ritual" by Revolution Void www.jamendo.com/en/list/a2225/increase-the-dosage * Awaiting verification by the FBI *** Warning: NSFW due to some harsh language, a few sexual references, and potential drunkenness of the hosts and/or guests. Listener discretion advised. © 2015, JonSquared Media

Treating low sex drive in women. Expert panels in the USA have voted in favour of a drug that has been dubbed 'Pink Viagra', but there are serious reservations. Outdoor swimming is the new trend for 2015, but should you take the plunge or go in slowly? Strokes in the under 55's have recently been reported to be on the increase: Dr Margaret McCartney takes a closer look at the evidence. And unpicking tricky terms to understand your health - causation versus association. Presented by Dr Mark Porter.